Key Highlights
- Jim Burns appointed as CEO and board member of Ensoma.
- Former leadership roles include CEO at Locanabio and Casebia Therapeutics.
- Focus on advancing precision genomic medicines using innovative technologies.
Source: Business Wire
Notable Quotes
- “Jim Burns is an accomplished biotechnology executive who joins Ensoma at a critical and exciting time for the company as we advance our first program through IND-enabling studies,” – Paula Soteropoulos, Chairman of the Board and Interim CEO at Ensoma
- “I am excited to join Ensoma’s highly talented team that is quickly advancing the next wave of genetic medicines,” – Jim Burns, Ph.D., CEO at Ensoma
SoHC's Take
The appointment of Jim Burns as CEO of Ensoma marks a significant milestone in the company’s journey towards revolutionizing genetic medicine. Burns’ proven leadership and extensive experience in the field of gene therapy are well-aligned with Ensoma’s innovative approach to treating genetic, immunological, and oncological diseases through its Engenious™ platform. This strategic leadership change promises to enhance Ensoma’s capabilities in advancing their pioneering technologies, potentially transforming the landscape of treatment for complex diseases with their in vivo cellular engineering solutions.
